Aims To evaluate the safety and efficacy of liver stereotactic body radiotherapy (SBRT) in the
treatment of unresectable hepatocellular carcinomas (HCC) measuring> 5 cm. Materials and …

Aims Stereotactic body radiotherapy (SBRT) is an option for the treatment of hepatocellular
carcinoma (HCC) in patients ineligible for standard local therapies. This study reports on the …

Objectives: To evaluate the outcomes of stereotactic radiotherapy (SBRT) in the treatment of
inoperable hepatocellular carcinomas (HCC) that are unsuitable for, or refractory to other …

Aims Intrahepatic progression remains the predominant mode of cancer-related death in
hepatocellular carcinoma (HCC) underscoring the need for effective local therapies. We …

Methods A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an
academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15 …

Purpose To describe outcomes of prospective trials of stereotactic body radiotherapy (SBRT)
for hepatocellular carcinoma (HCC). Patients and Methods Two trials of SBRT for patients …

Background. Since 2005, we have treated hepatocellular carcinoma (HCC) with stereotactic
body radiotherapy (SBRT) uniformly at two dose levels, according to baseline liver function …

Methods We retrospectively analyzed 36 patients (45 lesions) treated between 2011 and
2017. Twenty-seven had previous treatments. Current treatment consisted of SBRT alone …

Introduction Stereotactic body radiotherapy (SBRT) is an emerging, therapeutic option in the
management of hepatocellular carcinoma (HCC). A multicentre Liver Ablative Stereotactic …

Abstract Introduction Stereotactic Body Radiotherapy (SBRT) emerged as a valuable option
in early to advanced-stage Hepatocellular Carcinoma (HCC) as defined by Barcelona Clinic …